- cafead Oct 04, 2022 at 10:52: AM
via Kezar Life Sciences has announced plans to commence the Phase IIa PORTOLA clinical trial (KZR-616-208) of zetomipzomib to treat autoimmune hepatitis.
The move comes after the US Food and Drug Administration granted clearance for the Investigational New Drug (IND) application of Kezar Life Sciences for zetomipzomib.
article source
The move comes after the US Food and Drug Administration granted clearance for the Investigational New Drug (IND) application of Kezar Life Sciences for zetomipzomib.
article source